Replies to post #397562 on Anavex Life Sciences Corp (AVXL)

[LBSR TO DA MOON]

12x - where you at? Interested to hear his/her thoughts on the statement below (along with the thoughts of the other hardcore biotech geeks here)...

Here are some facts:
lecanemab primary endpoint was CDR-SB and data here with time course (to 18 months): https://www.nejm.org/doi/full/10.1056/NEJMoa2212948
Anavex-273 data with time course looks better at week 48 than at week 72 for lecanemab
The patients will be evaluated for Anavex-273 out to 96 weeks.
In other words apples to apples data comparison to lecanemab shows a better outcome for 273 using the primary endpoint that the FDA used to accept the drug for approval. I think this is pretty good and new

[AceT]

Slide with a few comparisions added: